Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
about
Available and emerging treatments for Parkinson's disease: a reviewLevodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatmentImpact of newer pharmacological treatments on quality of life in patients with Parkinson's diseaseNeuropathy in Parkinson's disease patients with intestinal levodopa infusion versus oral drugsAn update on the diagnosis and treatment of Parkinson diseaseDevelopment of new levodopa treatment strategies in Parkinson's disease-from bedside to bench to bedsideReview of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson'Dopamine agonist therapy in advanced Parkinson's diseaseContinuous drug delivery in Parkinson's disease.Dystonia in Parkinson's disease.Deep brain stimulation and responsiveness of the Persian version of Parkinson's disease questionnaire with 39-itemsCritical aspects of clinical trial design for novel cell and gene therapies.Health-related quality of life as an outcome variable in Parkinson's disease.Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safetyGene therapy for Parkinson's disease using recombinant adeno-associated viral vectors.Advances in the delivery of treatments for Parkinson's disease.Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label resultsImportance of the brain Angiotensin system in Parkinson's diseaseThe levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations.Levodopa, motor fluctuations and dyskinesia in Parkinson's disease.Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?Drug Insight: new drugs in development for Parkinson's disease.Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease.Impact of Duodopa on Quality of Life in Advanced Parkinson's Disease: A UK Case Series.The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experienceEffect of medical and surgical interventions on health-related quality of life in Parkinson's disease.Duodenal levodopa infusion for the treatment of Parkinson's disease.When should levodopa therapy be initiated in patients with Parkinson's disease?Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results.Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment.Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.Parkinson's disease: recent development in therapies for advanced disease with a focus on deep brain stimulation (DBS) and duodenal levodopa infusion.Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery?Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.Levodopa-induced dyskinesias and their management.Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based reviewWhat's in the pipeline for the treatment of Parkinson's disease?Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management.Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy.
P2860
Q24633444-FD9D0798-C442-4492-98D4-4788A75926F3Q24647141-A6B4E56A-358D-4EFC-975B-9DD42E9F5FDAQ28283547-A03BA22B-8D42-4E22-B07C-901477E67AB5Q28534024-BCDF783B-7B8E-438C-A737-222720A14356Q30243899-4B19FE6A-A3F1-4DBC-BA77-AC53C9033A51Q30852749-F3004354-13AC-4A16-87ED-A8D4C6E94528Q33260251-C8E1FAD0-9188-4ACC-8598-2ECFDFF6505CQ33636332-B3FDD48B-0F2D-4CA1-AA07-8FA09D1F5F10Q34390800-9A3B4D88-11CB-455F-8E77-5FB5C71B6700Q34585274-060B7D73-B1BF-4640-8038-F665C9734D64Q34991569-57EFE850-7B16-4C21-8233-F5A8D034C5F0Q35664438-CEF7AA76-E338-4BAB-A314-64CFECAA8031Q35825918-FDC64FEE-3F40-4B4D-AAA2-A3F731EA0727Q36025896-1DEAE573-39D4-42D8-BE50-64AC7461597BQ36150495-375C7C0D-9705-4D07-BC8D-2869665651EBQ36316936-AD043A29-E80F-4FAF-96BE-84BDF3571714Q36361513-9FC31CD8-EC40-40B3-9339-B0275F3C2A31Q36415423-C53DBE70-00A4-4EA9-91B1-3A5C27DAF15FQ36521884-B0522601-2359-49B8-9346-C6499B744260Q36573882-7F1919AC-9B92-46E7-9788-6E9DE4D04E22Q36587747-9A19AF75-768B-4D35-B7D6-98FB75260863Q36631654-631717FB-3CD6-49F1-84F7-857E54FF9558Q36641474-9C985C51-0390-47CF-96DB-9A1D2812EE83Q36651313-00C87BDF-12D8-43D2-A163-78C96CDF2F0EQ36724032-B7A1D5BB-AE8E-4D44-B55B-FE8FEED6F981Q36753631-9D95D653-DCB6-4A0F-8FD6-E9977B4E469CQ36765792-C5BD5E21-D3B3-4291-8E63-B9604228FAA8Q36791053-5EBE5C00-AF63-4388-84A9-F9CBDAC3D606Q36866618-3B7CB462-9733-4474-8ABF-27332CF4E891Q36873506-E9B4FB14-DC1F-4FA7-8D4A-2DB0AE26FD36Q36910602-8D929048-F32E-43F7-887C-4E996A50A3B8Q37086136-8E215E3F-E34F-49CD-8E25-5F45AFA94F85Q37115650-4E6D329C-444D-4ECB-A09B-EC2E83DE7132Q37264446-F01BE4C2-75C5-408B-B486-A621D557942AQ37264464-D216C38D-2E97-462F-A7E0-A730C571A008Q37280804-99D7388C-21AB-4E04-9581-0F47599A508FQ37302240-AB9AEF63-A896-4698-8841-94281BD1EDB4Q37352050-0A65636D-C741-4DFF-A5D4-9AEF595B4820Q37507973-5C99B222-CCC5-45CB-ABF4-C637D327F630Q37643232-5D2ED83B-47C8-45B8-993A-FA929FC33E95
P2860
Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Duodenal levodopa infusion mon ...... in advanced Parkinson disease.
@ast
Duodenal levodopa infusion mon ...... in advanced Parkinson disease.
@en
Duodenal levodopa infusion mon ...... in advanced Parkinson disease.
@nl
type
label
Duodenal levodopa infusion mon ...... in advanced Parkinson disease.
@ast
Duodenal levodopa infusion mon ...... in advanced Parkinson disease.
@en
Duodenal levodopa infusion mon ...... in advanced Parkinson disease.
@nl
prefLabel
Duodenal levodopa infusion mon ...... in advanced Parkinson disease.
@ast
Duodenal levodopa infusion mon ...... in advanced Parkinson disease.
@en
Duodenal levodopa infusion mon ...... in advanced Parkinson disease.
@nl
P2093
P1433
P1476
Duodenal levodopa infusion mon ...... in advanced Parkinson disease.
@en
P2093
Aquilonius SM
Constantinescu R
Holmberg B
Nilsson Remahl AI
P304
P356
10.1212/01.WNL.0000149637.70961.4C
P407
P577
2005-01-01T00:00:00Z